期刊文献+

消瘤汤加减干预对结直肠癌术后血管内皮生长因子及中医证候的影响 被引量:2

Effect of modified Xiaoliu decoction intervention on vascular endothelial growth factor and traditional Chinese medicine syndrome after colorectal cancer operation
下载PDF
导出
摘要 目的观察消瘤汤加减干预对结直肠癌术后血管内皮生长因子(VEGF)及中医证候的影响。方法将200例结直肠癌术后患者随机分为治疗组和对照组,各100例。两组均采用腹腔内热灌注化疗。结合中医辨证论治方法,治疗组根据患者相应的证型予以加减消瘤汤治疗。比较两组患者的治疗前后VEGF水平、治疗后生存质量改善情况,并根据治疗前后中医临床主症改变情况评价治疗效果。结果治疗后,两组患者VEGF水平均较治疗前明显降低,且治疗组VEGF水平明显低于对照组(均P<0.05);治疗组生存质量改善情况明显优于对照组(P<0.05);治疗组患者的中医证候总有效率为64.0%(64/100),对照组的总有效率为29.0%(29/100),两组总有效率比较,差异有统计学意义(P<0.05)。结论消瘤汤对结直肠癌患者VEGF的表达有抑制作用,可在一定程度上预防结直肠癌患者术后转移、复发,同时可有效改善中医证候,提高患者生存质量。 Objective To observe the effect of modified Xiaoliu decoction intervention on vascular endothelial growth factor(VEGF)and traditional Chinese medicine syndrome after colorectal cancer operation.Methods A total of 200 patients after colorectal cancer operation were randomly divided into treatment group and control group,with 100 cases in each group.Both groups were given intraperitoneal chemohyperthermia.Combining with the method of traditional Chinese medicine syndrome differentiation,the treatment group was treated with modified Xiaoliu decoction according to the corresponding syndrome types.The levels of VEGF before and after treatment,and the improvement of life quality after treatment were compared between the two groups,as well as the therapeutic effect was evaluated based on the changes of clinical main symptoms of traditional Chinese medicine before and after treatment.Results After treatment,the levels of VEGF in the two groups decreased as compared with those before treatment,and the treatment group yielded a lower level compared to the control group(all P<0.05).A significantly superior improvement of life quality revealed in the treatment group than in the control group(P<0.05).The total effective rate of traditional Chinese medicine syndrome in the treatment group was 64.0%(64/100),with 29.0%(29/100)in the control group,and there was a statistically significant difference in the total effective rate between the two groups(P<0.05).Conclusion Xiaoliu decoction can inhibit the expression of VEGF in patients with colorectal cancer,which may have prevention on postoperative metastasis and recurrence in patients after colorectal cancer operation to a certain extent;meanwhile,it can effectively improve the traditional Chinese medicine syndrome and the life quality of patients.
作者 曾家耀 吴西西 蓝洪波 周路 蔡菲菲 ZENG Jiayao;WU Xixi;LAN Hongbo;ZHOU Lu;CAI Feifei(The First Affiliated Hospital of Guangxi University of Chinese Medicine,Nanning 530023,Guangxi,China;Guangxi International Zhuang Medicine Hospital,Nanning 530001,Guangxi,China)
出处 《微创医学》 2021年第5期612-615,共4页 Journal of Minimally Invasive Medicine
基金 国家自然科学基金项目(编号:81360546) 广西壮族自治区科技厅重点研发计划项目(编号:桂科AB16380227)。
关键词 结直肠癌 术后 腹腔内热灌注化疗 消瘤汤 血管内皮生长因子 中医证候 Colorectal cancer After operation Intraperitoneal chemohyperthermia Xiaoliu decoction Vascular endothelial growth factor Traditional Chinese medicine syndrome
  • 相关文献

参考文献7

二级参考文献74

  • 1付志荣,蔡玲.谈患者用药依从性与临床疗效的关系[J].时珍国医国药,2005,16(10):1056-1057. 被引量:26
  • 2Cats A. New development in systemic chemotherapy in advanced colorectal cancer [J]. Seand J Gastroenterol Suppl, 2003, (239) : 78-86.
  • 3The Advanced Colorectal Cancer MetaAnalysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate [J]. J Clin Oncol, 1992,10(6) : 896-903.
  • 4Poon M A, O'Connell M J, Wieand H S, et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer [J]. J Clin Oncol, 1991,9(11):1967- 1972.
  • 5de Gramont A, Bosset J F, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly highdose leucovorin and fluoronracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup study [J]. J Clin Oncol, 1997,15(2): 808-815.
  • 6Machover D, Diaz-Rubio E, de Gramont A, et al. Two consecutive phase Ⅱ studies of oxaliplatin (LOHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluorepyrimidines [J]. Ann Oncol, 1996,7( 1 ) :95-98.
  • 7Becouarn Y, Ychou M, Ducreux M, et al. Phase H trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers [J]. J Clin Oncol, 1998,16 ( 8 ) : 2739-2744.
  • 8Giacchetti S, Perpoint B, Zidani R, et al. Phase Ⅲ muhicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer [J]. J Clin Oncol, 2000,18( 1 ) : 136-147.
  • 9de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J]. J Clin Oncol, 2000,18(16): 2938-2947.
  • 10Conti J A, Kemeny N E, Saltz L B,et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer [J]. J Clin Oncol, 1996, 14(3) :709-715.

共引文献198

同被引文献28

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部